Biogen scraps two late-stage trials for Alzheimer’s treatment

Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. Reuters Health News

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.